Adsorptive Granulocyte/Monocyte Apheresis for the Maintenance of Remission in Patients with Ulcerative Colitis: A Prospective Randomized, Double Blind, Sham-Controlled Clinical Trial
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Weekly granulocyte/monocyte adsorption (GMA) to deplete elevated and activated leucocytes should serve as a non-pharmacological intervention to induce remission in patients with ulcerative colitis (UC). This trial assessed the efficacy of monthly GMA as a maintenance therapy to suppress UC relapse. Methods: Thirty-three corticosteroid refractory patients with active UC received 10 weekly GMA sessions as a remission induction therapy. They were then randomized to receive one GMA session every 4 weeks (True, n=11), extracorporeal circulation without the GMA column every 4 weeks (Sham, n=11), or no additional intervention (Control, n=11). The primary endpoint was the rate of avoiding relapse (AR) over 48 weeks. Results: At week 48, the AR rates in the True, Sham, and Control groups were 40.0%, 9.1%, and 18.2%, respectively. All patients were steroid-free, but no statistically significant difference was seen among the three arms. However, in patients who could taper their prednisolone dose to <20 mg/day during the remission induction therapy, the AR in the True group was better than in the Sham (p<0.03) or Control (p<0.05) groups. Conclusions: Monthly GMA may potentially prevent UC relapse in patients who have achieved remission through weekly GMA, especially in patients on <20 mg/day PSL at the start of the maintenance therapy.
Abstract
Background/Aims: Weekly granulocyte/monocyte adsorption (GMA) to deplete elevated and activated leucocytes should serve as a non-pharmacological intervention to induce remission in patients with ulcerative colitis (UC). This trial assessed the efficacy of monthly GMA as a maintenance therapy to suppress UC relapse. Methods: Thirty-three corticosteroid refractory patients with active UC received 10 weekly GMA sessions as a remission induction therapy. They were then randomized to receive one GMA session every 4 weeks (True, n=11), extracorporeal circulation without the GMA column every 4 weeks (Sham, n=11), or no additional intervention (Control, n=11). The primary endpoint was the rate of avoiding relapse (AR) over 48 weeks. Results: At week 48, the AR rates in the True, Sham, and Control groups were 40.0%, 9.1%, and 18.2%, respectively. All patients were steroid-free, but no statistically significant difference was seen among the three arms. However, in patients who could taper their prednisolone dose to <20 mg/day during the remission induction therapy, the AR in the True group was better than in the Sham (p<0.03) or Control (p<0.05) groups. Conclusions: Monthly GMA may potentially prevent UC relapse in patients who have achieved remission through weekly GMA, especially in patients on <20 mg/day PSL at the start of the maintenance therapy.
참고문헌 (23)
- Isaacs KL, "State of the art: IBD therapy and clinical trials in IBD", Inflamm Bowel Dis, 11(Suppl 1), pp.S3~S12 (2005)
- Saniabadi AR, "Therapeutic leukocytapheresis for inflammatory bowel disease", Transfus Apher Sci, 37, pp.191~200 (2007)
- Allison MC, "Inflammatory bowel disease", pp.9~95 (1998), Mosby
- Shimoyama T, "Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study", J Clin Apher, 16, pp.1~9 (2001)
- Ken Fukunaga, "Cytapheresis in Patients with Severe Ulcerative Colitis after Failure of Intravenous Corticosteroid: A Long-Term Retrospective Cohort Study", Gut and Liver, 3(1), pp.41~47 (2009), 거트앤리버 발행위원회
- Sawada K, "Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column", Curr Pharm Des, 9, pp.307~321 (2003)
- Lichtiger S, "Cyclosporine in severe ulcerative colitis refractory to steroid therapy", N Engl J Med, 330, pp.1841~1845 (1994)
- Nagase K, "Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant", Ther Apher Dial, 8, pp.45~51 (2004)
- Sands BE, "A randomized, double-blind, sham-controlled study of granulocyte", monocyte apheresis for active ulcerative colitis, 2008, pp.135, 400~409
- Yoshino T, "Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants", Digestion, 84, pp.3~9 (2011)
- Domènech E, "Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study", Aliment Pharmacol Ther, 20, pp.1347~1352 (2004)
- Tanaka T, "In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naive patients", Dig Liver Dis, 40, pp.731~736 (2008)
- Hibi T, "Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan", Dig Liver Dis, 41, pp.570~577 (2009)
- Present DH, "How to do without steroids in inflammatory bowel disease", Inflamm Bowel Dis, 6, pp.48~57 (2000)
- Brown SL, "Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration", Arthritis Rheum, 46, pp.3151~3158 (2002)
- Yamamoto T, "Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings", Inflamm Bowel Dis, 12, pp.719~726 (2006)
- Suzuki Y, "A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis", Dig Dis Sci, 51, pp.2031~2038 (2006)
- Sakuraba A, "An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment", Am J Gastroenterol, 104, pp.2990~2995 (2009)
- Bresci G, "Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow-up", J Gastroenterol Hepatol, 23, pp.1678~1682 (2008)
- Maiden L, "Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse", Inflamm Bowel Dis, 14, pp.1413~1418 (2008)
- Schwartz D, "Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte", monocyte apheresis, 2007, pp.23, 2715~2728
- Abreu MT, "Selective leukocyte apheresis for the treatment of inflammatory bowel disease", J Clin Gastroenterol, 41, pp.874~888 (2007)
- Hanai H, "Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study", Dig Liver Dis, 40, pp.433~440 (2008)